Professor Emma Hamilton-Williams

Professor Emma Hamilton-Williams leads the Type 1 diabetes pathogenesis and therapy group.
Research projects
- Early-life factors and the gut microbiota as drivers of islet autoimmunity and type 1 diabetes
- Gut-microbiome targeted therapeutics for type 1 diabetes
- Antigen-specific immunotherapy for type 1 diabetes
- Molecular mechanisms of tolerance for suppression of autoreactive T cells
Researcher biography
Associate Professor Emma Hamilton-Williams' career focuses on understanding how immune tolerance is disrupted leading to the development of the autoimmune disease type 1 diabetes. She received her PhD from the Australian National University in 2001, followed by postdoctoral training in Germany and the Scripps Research Institute in the USA.
In 2012, she started a laboratory at the Frazer Institute, University of Queensland where she investigates the gut microbiota as a potential trigger or therapy target for type 1 diabetes, as well as developing an immunotherapy for type 1 diabetes. The overall aim of her research is to find new ways to prevent or treat the underlying immune dysfunction causing autoimmunity.
She is Chief Scientific Officer for an Australia-wide pregnancy-birth cohort study of children at increased risk of type 1 diabetes, which aims to uncover the environmental drivers of this disease. Her laboratory uses big-data approaches including proteomics, metabolomics and metagenomics to understand the function of the gut microbiota linked to disease.
She recently conducted a clinical trial of a microbiome-targeting biotherapy aimed at restoring a healthy microbiome and immune tolerance, with an ultimate aim of preventing type 1 diabetes.